Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04707664 · ClinicalTrials.gov registry record · Phase 2
Sargramostim Use in COVID-19 to Recover Patient Health
A Phase 2 study, sponsored by Partner Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 600
- Enrollment target
NCT04707664: Completed Phase 2 study, sponsored by Partner Therapeutics.
NCT04707664 is a Phase 2 study that has completed, run by Partner Therapeutics. The registered enrollment target is 600 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (351% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04707664, a Phase 2 study, has completed, sponsored by Partner Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 600 participants
- Enrollment target
Study Summary
The purpose of this research is to understand if the study drug, also called sargramostim or Leukine®, can help prevent the worsening of COVID-19 when the study drug is inhaled. This study will also help researchers understand if inhaled sargramostim can help prevent visits to the emergency room or hospitalization, or death.
Primary Outcome
Percentage of patients who experience any emergency room visit or hospitalization, or death
Interventions
- DRUG Placebo
- DRUG Sargramostim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2021-04-27 |
| Est. Completion | 2022-01-31 |
| Phase | Phase 2 |
What the finished NCT04707664 record still lists
NCT04707664 is an interventional study that assigns participants to a tested intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (351% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04707664 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04707664 about?
NCT04707664 is a clinical study titled "Sargramostim Use in COVID-19 to Recover Patient Health". The purpose of this research is to understand if the study drug, also called sargramostim or Leukine®, can help prevent the worsening of COVID-19 when the study drug is inhaled. This study will also help researchers understand if inhaled sargramostim can help prevent visits to the emergency room or ...
What is the current status of trial NCT04707664?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 600 participants. The study started on 2021-04-27. Estimated completion is 2022-01-31.
What interventions are being tested in trial NCT04707664?
The interventions under investigation include: Placebo (DRUG), Sargramostim (DRUG).
Who is sponsoring clinical trial NCT04707664?
This trial is sponsored by Partner Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04707664's enrollment target sits among peer trials
600 53rd of 2000 higher than 1,945 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI